Let cholesterol "discharge"!The Wuhan University team discovered that it appeared on "Nature"

Ji Mu Journalist Ke said

Correspondent Wu Jianglong Xing Zhibo

Intern Zhao Huaizhi Chen Lin

Another Song Baoliang team in Wuhan University! It is a new strategy of lipid -lowering! It was published again on top journals!

On August 3, Professor Song Baoliang Laboratory of the Chinese Academy of Sciences and Dean of the School of Life Sciences of Wuhan University published a paper in Nature (Nature "), revealing a new strategy to reduce blood lipids. The first author of the paper Wang Juqiong, a post -doctoral school of the School of Life Sciences of Wu Da, said in an interview with polar news news: "Previous drugs were suppressed cholesterol synthesis or absorption, and our research first found a solution that effectively promoted the external arrangement of cholesterol."

Nature screenshot

6 years have worked hard to unveil the genetic password

Cholesterol is a lipid substance that causes headaches for many people. Its metabolic level is closely related to cardiovascular and cerebrovascular diseases such as stroke and coronary heart disease. Lipidation is a necessary means to prevent and treat cardiovascular disease.

It is understood that Hisine, Yizhuo Maibu, and PCSK9 inhibitors are currently common lipid -lowering drugs, but researchers believe that although they can reduce blood lipids to varying degrees, there are certain side effects and limitations, such as Besine and PCSK9 suppression The risk of the liver burden is increased, and the lipid reduction of the compromise is limited.

Academician Song Baoliang instructed Wang Juqiong (right)

In 2016, a foreign study found that ASGR1 gene mutations were related to hypolipidal lipids, but the molecule was not clear. Since then, Wang Juqiong has been aiming at the gene, trying to unveil the "password" of lipid -lowering behind it. Wang Juqiong said: "Human cells are difficult to degrade cholesterol molecules efficiently. If it can be excreted to the human body in the human body, it will be an ideal lipid -lowering strategy. What I have done in the past 6 years is to figure out how the ASGR1 gene mutations affect blood lipids and make reasonable use in the future. It finds a breakthrough. "

By lipid -lowering through the form of cholesterol, other research teams have also tried, but there is no precedent for success. Wang Juqiong and his team partners made hard efforts, and finally found that inhibiting ASGR1 caused increased expression of ABCG5 and ABCG8, the latter discharged cholesterol into bile, and cholesterol further left the body through feces, which greatly reduced blood and liver lipid levels.

Inhibit the deprivanide sugar protein receptor ASGR1 promotes cholesterol exhaust

The researchers also developed the neutral antibody of ASGR1. The antibody can effectively promote cholesterol and have a good coordinated lipid -lowering effect with Catiner and Yichemu. "This antibody can be understood as a prototype of a drug. We tested on mice and found that it could reduce the total serum cholesterol level of mice by 50%, and at the same time reduced the serum triglyceride level by 22%." Wang Juqiong Qiong Qiongqiong Said that this research laid an important foundation for the research and development of lipid -lowering drugs that prompting cholesterol.

"In the future, there will be a new drug that promotes cholesterol. If the blood lipids are slightly higher, you can use the medicine alone. If other circumstances can also be considered with existing drugs to produce better results." Wang Juqiong thought.

Post -70s academician specializing in cholesterol

Wang Juqiong was a post -90s. Since being admitted to the School of Life Sciences of Wuhan University, he has joined Song Bao Liang's team for 8 years.

In 8 years, Wang Juqiong has been busy for this subject for 6 years. She said that after countless times, she was lost and confused, "but I have never doubted myself, I think the direction is right, and Teacher Song thinks so. Specific guidance, he will also check the literature for me. "

Wang Juqiong (left) took a group photo with Academician Song Baoliang

In the field of cholesterol metabolism research, Song Baoliang, who is only 47 years old, is authoritative. He has obtained a series of important original discovery: the molecular pathway to clarify the absorption of small intestinal cholesterol, reveal a new way and method of discovering a cholesterol synthesis regulatory pathway, and the discovery of intracellular cholesterol transportation. It has made important contributions to my country's fat metabolism research. Song Baoliang and his team published more than 40 papers with the author (including common communication), including Nature, Science, Cell, etc., and were twice selected as "Top Ten Progress of China Life Sciences" in 2015 and 2020.

In 2014, Song Baoliang was the dean of the School of Life Sciences of Wuhan University and was the youngest dean of Wuhan University at that time. In 2021, Song Baoliang was elected academician of the Chinese Academy of Sciences. He was the youngest of Hubei was elected academician of the two academies.

Song Baoliang team member (part)

Wang Juqiong said that with such young and promising team leaders, the entire team is very motivated. "The research atmosphere of our team is also very good. Everyone is very cooperative. This papers can be published in" Nature ", which is the result of the entire team's efforts. We have done basic research. In the future Develop. "Wang Juqiong said.

(The picture is provided by the respondent)

- END -